AustralieFrV1, Main, Exploration, bibRecord, 005123

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

Identifieur interne : 005123 ( Main/Exploration ); précédent : 005122; suivant : 005124

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

Auteurs : Luca Gianni ; Gilles H. Romieu [France] ; Michail Lichinitser [Russie] ; Sergio V. Serrano [Brésil] ; Mauro Mansutti [Italie] ; Xavier Pivot [France] ; Paola Mariani [Italie] ; Fabrice Andre [France] ; Arlene Chan [Australie] ; Oleg Lipatov [Royaume-Uni] ; Stephen Chan [Royaume-Uni] ; Andrew Wardley [Royaume-Uni] ; Richard Greil [Autriche] ; Nicola Moore [Suisse] ; Sylvie Prot [Suisse] ; Celine Pallaud [Suisse] ; Vladimir Semiglazov [Russie]

Source :

Journal of clinical oncology [ 0732-183X ] ; 2013.

RBID : Pascal:13-0188852

Descripteurs français

Pascal (Inist)
- Essai clinique phase III, Essai clinique, Randomisation, Bévacizumab, Association médicamenteuse, Trastuzumab, Chimiothérapie, Anticorps monoclonal, Gène onc cellulaire, Docétaxel, Protooncogène, Gène erbB2, Traitement de première intention, Récidive, Récidivant, Stade avancé, Métastase, Cancer du sein, Glande mammaire, Cancérologie, Facteur croissance endothélium vasculaire, Anticancéreux, Immunomodulateur, Antiangiogénique, Niveau local, Récepteur HER2.

English descriptors

KwdEn :
- Advanced stage, Antiangiogenic agent, Antineoplastic agent, Bevacizumab, Breast cancer, C-Onc gene, Cancerology, Chemotherapy, Clinical trial, Docetaxel, Drug combination, First line treatment, Human Epidermal growth factor Receptor 2, Immunomodulator, Mammary gland, Metastasis, Monoclonal antibody, Phase III trial, Protooncogene, Randomization, Recurrent, Relapse, Trastuzumab, Vascular endothelium growth factor, erbB2 Gene.

Abstract

Purpose The AVEREL trial [A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer] evaluated first-line bevacizumab-containing therapy for human epidermal growth factor receptor 2 (HER2) -positive locally recurrent/metastatic breast cancer (LR/MBC). Patients and Methods Patients with measurable/evaluable HER2-positive LR/MBC who had not received trastuzumab or chemotherapy for LR/MBC were stratified by prior adjuvant trastuzumab, prior (neo)adjuvant taxane, hormone receptor status, and measurable disease and were randomly assigned to receive docetaxel 100 mg/m² plus trastuzumab 8 mg/kg loading dose followed by 6 mg/kg either with bevacizumab 15 mg/kg or without bevacizumab, all administered every 3 weeks. The primary end point was progression-free survival (PFS). Additional end points included overall survival, response rate (RR), safety, quality of life, and translational research.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000A38
to stream PascalFrancis, to step Curation: 005434
to stream PascalFrancis, to step Checkpoint: 000B39
to stream Main, to step Merge: 005313
to stream Main, to step Curation: 005123

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer</title>
<author><name sortKey="Gianni, Luca" sort="Gianni, Luca" uniqKey="Gianni L" first="Luca" last="Gianni">Luca Gianni</name>
<affiliation><inist:fA14 i1="01"><s1>Ospedale San Raffaele</s1>
<s3>INC</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<wicri:noCountry>INC</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Romieu, Gilles H" sort="Romieu, Gilles H" uniqKey="Romieu G" first="Gilles H." last="Romieu">Gilles H. Romieu</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Centre Régionale de Lutte contre le Cancer, Val d'Aurelle</s1>
<s2>Montpellier</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lichinitser, Michail" sort="Lichinitser, Michail" uniqKey="Lichinitser M" first="Michail" last="Lichinitser">Michail Lichinitser</name>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>N.N. Blokhin Russian Oncolog Research Center</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Russie</country>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Serrano, Sergio V" sort="Serrano, Sergio V" uniqKey="Serrano S" first="Sergio V." last="Serrano">Sergio V. Serrano</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Fundação Pio XII Hospital de Câncer de Barretos</s1>
<s2>Barretos</s2>
<s3>BRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Brésil</country>
<wicri:noRegion>Fundação Pio XII Hospital de Câncer de Barretos</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mansutti, Mauro" sort="Mansutti, Mauro" uniqKey="Mansutti M" first="Mauro" last="Mansutti">Mauro Mansutti</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University Hospital of Udine</s1>
<s2>Udine</s2>
<s3>ITA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>University Hospital of Udine</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pivot, Xavier" sort="Pivot, Xavier" uniqKey="Pivot X" first="Xavier" last="Pivot">Xavier Pivot</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>University Hospital Jean Minjoz</s1>
<s2>Besançon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Franche-Comté</region>
<settlement type="city">Besançon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mariani, Paola" sort="Mariani, Paola" uniqKey="Mariani P" first="Paola" last="Mariani">Paola Mariani</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="Andre">Fabrice Andre</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Gustave Roussy Institute</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Gustave Roussy Institute</wicri:noRegion>
<wicri:noRegion>Gustave Roussy Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chan, Arlene" sort="Chan, Arlene" uniqKey="Chan A" first="Arlene" last="Chan">Arlene Chan</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Mount Hospital</s1>
<s2>Perth</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Mount Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lipatov, Oleg" sort="Lipatov, Oleg" uniqKey="Lipatov O" first="Oleg" last="Lipatov">Oleg Lipatov</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Republican Clinical Oncology Dispensary</s1>
<s2>Ufa</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Republican Clinical Oncology Dispensary</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chan, Stephen" sort="Chan, Stephen" uniqKey="Chan S" first="Stephen" last="Chan">Stephen Chan</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Nottingham University Hospitals National Health Service (NHS) Trust</s1>
<s2>Nottingham</s2>
<s3>GBR</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Nottingham University Hospitals National Health Service (NHS) Trust</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wardley, Andrew" sort="Wardley, Andrew" uniqKey="Wardley A" first="Andrew" last="Wardley">Andrew Wardley</name>
<affiliation wicri:level="3"><inist:fA14 i1="13"><s1>The Christie NHS Foundation Trust</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Greil, Richard" sort="Greil, Richard" uniqKey="Greil R" first="Richard" last="Greil">Richard Greil</name>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Paracelsus Medical University</s1>
<s2>Salzburg</s2>
<s3>AUT</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<wicri:noRegion>Paracelsus Medical University</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moore, Nicola" sort="Moore, Nicola" uniqKey="Moore N" first="Nicola" last="Moore">Nicola Moore</name>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>F. Hoffmann-La Roche</s1>
<s2>Basel</s2>
<s3>CHE</s3>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>F. Hoffmann-La Roche</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Prot, Sylvie" sort="Prot, Sylvie" uniqKey="Prot S" first="Sylvie" last="Prot">Sylvie Prot</name>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>F. Hoffmann-La Roche</s1>
<s2>Basel</s2>
<s3>CHE</s3>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>F. Hoffmann-La Roche</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pallaud, Celine" sort="Pallaud, Celine" uniqKey="Pallaud C" first="Celine" last="Pallaud">Celine Pallaud</name>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>F. Hoffmann-La Roche</s1>
<s2>Basel</s2>
<s3>CHE</s3>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>F. Hoffmann-La Roche</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Semiglazov, Vladimir" sort="Semiglazov, Vladimir" uniqKey="Semiglazov V" first="Vladimir" last="Semiglazov">Vladimir Semiglazov</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>N.N. Petrov Research Institute of Oncology</s1>
<s2>St. Petersburg</s2>
<s3>RUS</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>Russie</country>
<wicri:noRegion>N.N. Petrov Research Institute of Oncology</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0188852</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0188852 INIST</idno>
<idno type="RBID">Pascal:13-0188852</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A38</idno>
<idno type="wicri:Area/PascalFrancis/Curation">005434</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000B39</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000B39</idno>
<idno type="wicri:doubleKey">0732-183X:2013:Gianni L:averel:a:randomized</idno>
<idno type="wicri:Area/Main/Merge">005313</idno>
<idno type="wicri:Area/Main/Curation">005123</idno>
<idno type="wicri:Area/Main/Exploration">005123</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer</title>
<author><name sortKey="Gianni, Luca" sort="Gianni, Luca" uniqKey="Gianni L" first="Luca" last="Gianni">Luca Gianni</name>
<affiliation><inist:fA14 i1="01"><s1>Ospedale San Raffaele</s1>
<s3>INC</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<wicri:noCountry>INC</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Romieu, Gilles H" sort="Romieu, Gilles H" uniqKey="Romieu G" first="Gilles H." last="Romieu">Gilles H. Romieu</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Centre Régionale de Lutte contre le Cancer, Val d'Aurelle</s1>
<s2>Montpellier</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lichinitser, Michail" sort="Lichinitser, Michail" uniqKey="Lichinitser M" first="Michail" last="Lichinitser">Michail Lichinitser</name>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>N.N. Blokhin Russian Oncolog Research Center</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Russie</country>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Serrano, Sergio V" sort="Serrano, Sergio V" uniqKey="Serrano S" first="Sergio V." last="Serrano">Sergio V. Serrano</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Fundação Pio XII Hospital de Câncer de Barretos</s1>
<s2>Barretos</s2>
<s3>BRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Brésil</country>
<wicri:noRegion>Fundação Pio XII Hospital de Câncer de Barretos</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mansutti, Mauro" sort="Mansutti, Mauro" uniqKey="Mansutti M" first="Mauro" last="Mansutti">Mauro Mansutti</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University Hospital of Udine</s1>
<s2>Udine</s2>
<s3>ITA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>University Hospital of Udine</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pivot, Xavier" sort="Pivot, Xavier" uniqKey="Pivot X" first="Xavier" last="Pivot">Xavier Pivot</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>University Hospital Jean Minjoz</s1>
<s2>Besançon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Franche-Comté</region>
<settlement type="city">Besançon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mariani, Paola" sort="Mariani, Paola" uniqKey="Mariani P" first="Paola" last="Mariani">Paola Mariani</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="Andre">Fabrice Andre</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Gustave Roussy Institute</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Gustave Roussy Institute</wicri:noRegion>
<wicri:noRegion>Gustave Roussy Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chan, Arlene" sort="Chan, Arlene" uniqKey="Chan A" first="Arlene" last="Chan">Arlene Chan</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Mount Hospital</s1>
<s2>Perth</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Mount Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lipatov, Oleg" sort="Lipatov, Oleg" uniqKey="Lipatov O" first="Oleg" last="Lipatov">Oleg Lipatov</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Republican Clinical Oncology Dispensary</s1>
<s2>Ufa</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Republican Clinical Oncology Dispensary</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chan, Stephen" sort="Chan, Stephen" uniqKey="Chan S" first="Stephen" last="Chan">Stephen Chan</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Nottingham University Hospitals National Health Service (NHS) Trust</s1>
<s2>Nottingham</s2>
<s3>GBR</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Nottingham University Hospitals National Health Service (NHS) Trust</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wardley, Andrew" sort="Wardley, Andrew" uniqKey="Wardley A" first="Andrew" last="Wardley">Andrew Wardley</name>
<affiliation wicri:level="3"><inist:fA14 i1="13"><s1>The Christie NHS Foundation Trust</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Greil, Richard" sort="Greil, Richard" uniqKey="Greil R" first="Richard" last="Greil">Richard Greil</name>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Paracelsus Medical University</s1>
<s2>Salzburg</s2>
<s3>AUT</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<wicri:noRegion>Paracelsus Medical University</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moore, Nicola" sort="Moore, Nicola" uniqKey="Moore N" first="Nicola" last="Moore">Nicola Moore</name>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>F. Hoffmann-La Roche</s1>
<s2>Basel</s2>
<s3>CHE</s3>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>F. Hoffmann-La Roche</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Prot, Sylvie" sort="Prot, Sylvie" uniqKey="Prot S" first="Sylvie" last="Prot">Sylvie Prot</name>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>F. Hoffmann-La Roche</s1>
<s2>Basel</s2>
<s3>CHE</s3>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>F. Hoffmann-La Roche</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pallaud, Celine" sort="Pallaud, Celine" uniqKey="Pallaud C" first="Celine" last="Pallaud">Celine Pallaud</name>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>F. Hoffmann-La Roche</s1>
<s2>Basel</s2>
<s3>CHE</s3>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>F. Hoffmann-La Roche</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Semiglazov, Vladimir" sort="Semiglazov, Vladimir" uniqKey="Semiglazov V" first="Vladimir" last="Semiglazov">Vladimir Semiglazov</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>N.N. Petrov Research Institute of Oncology</s1>
<s2>St. Petersburg</s2>
<s3>RUS</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>Russie</country>
<wicri:noRegion>N.N. Petrov Research Institute of Oncology</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term>
<term>Antiangiogenic agent</term>
<term>Antineoplastic agent</term>
<term>Bevacizumab</term>
<term>Breast cancer</term>
<term>C-Onc gene</term>
<term>Cancerology</term>
<term>Chemotherapy</term>
<term>Clinical trial</term>
<term>Docetaxel</term>
<term>Drug combination</term>
<term>First line treatment</term>
<term>Human Epidermal growth factor Receptor 2</term>
<term>Immunomodulator</term>
<term>Mammary gland</term>
<term>Metastasis</term>
<term>Monoclonal antibody</term>
<term>Phase III trial</term>
<term>Protooncogene</term>
<term>Randomization</term>
<term>Recurrent</term>
<term>Relapse</term>
<term>Trastuzumab</term>
<term>Vascular endothelium growth factor</term>
<term>erbB2 Gene</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Essai clinique phase III</term>
<term>Essai clinique</term>
<term>Randomisation</term>
<term>Bévacizumab</term>
<term>Association médicamenteuse</term>
<term>Trastuzumab</term>
<term>Chimiothérapie</term>
<term>Anticorps monoclonal</term>
<term>Gène onc cellulaire</term>
<term>Docétaxel</term>
<term>Protooncogène</term>
<term>Gène erbB2</term>
<term>Traitement de première intention</term>
<term>Récidive</term>
<term>Récidivant</term>
<term>Stade avancé</term>
<term>Métastase</term>
<term>Cancer du sein</term>
<term>Glande mammaire</term>
<term>Cancérologie</term>
<term>Facteur croissance endothélium vasculaire</term>
<term>Anticancéreux</term>
<term>Immunomodulateur</term>
<term>Antiangiogénique</term>
<term>Niveau local</term>
<term>Récepteur HER2</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose The AVEREL trial [A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer] evaluated first-line bevacizumab-containing therapy for human epidermal growth factor receptor 2 (HER2) -positive locally recurrent/metastatic breast cancer (LR/MBC). Patients and Methods Patients with measurable/evaluable HER2-positive LR/MBC who had not received trastuzumab or chemotherapy for LR/MBC were stratified by prior adjuvant trastuzumab, prior (neo)adjuvant taxane, hormone receptor status, and measurable disease and were randomly assigned to receive docetaxel 100 mg/m<sup>2</sup>
 plus trastuzumab 8 mg/kg loading dose followed by 6 mg/kg either with bevacizumab 15 mg/kg or without bevacizumab, all administered every 3 weeks. The primary end point was progression-free survival (PFS). Additional end points included overall survival, response rate (RR), safety, quality of life, and translational research.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>Autriche</li>
<li>Brésil</li>
<li>France</li>
<li>Italie</li>
<li>Royaume-Uni</li>
<li>Russie</li>
<li>Suisse</li>
</country>
<region><li>Angleterre</li>
<li>Bourgogne-Franche-Comté</li>
<li>District fédéral central</li>
<li>Franche-Comté</li>
<li>Grand Manchester</li>
<li>Languedoc-Roussillon</li>
<li>Lombardie</li>
<li>Occitanie (région administrative)</li>
</region>
<settlement><li>Besançon</li>
<li>Manchester</li>
<li>Milan</li>
<li>Montpellier</li>
<li>Moscou</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Gianni, Luca" sort="Gianni, Luca" uniqKey="Gianni L" first="Luca" last="Gianni">Luca Gianni</name>
</noCountry>
<country name="France"><region name="Occitanie (région administrative)"><name sortKey="Romieu, Gilles H" sort="Romieu, Gilles H" uniqKey="Romieu G" first="Gilles H." last="Romieu">Gilles H. Romieu</name>
</region>
<name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="Andre">Fabrice Andre</name>
<name sortKey="Pivot, Xavier" sort="Pivot, Xavier" uniqKey="Pivot X" first="Xavier" last="Pivot">Xavier Pivot</name>
</country>
<country name="Russie"><region name="District fédéral central"><name sortKey="Lichinitser, Michail" sort="Lichinitser, Michail" uniqKey="Lichinitser M" first="Michail" last="Lichinitser">Michail Lichinitser</name>
</region>
<name sortKey="Semiglazov, Vladimir" sort="Semiglazov, Vladimir" uniqKey="Semiglazov V" first="Vladimir" last="Semiglazov">Vladimir Semiglazov</name>
</country>
<country name="Brésil"><noRegion><name sortKey="Serrano, Sergio V" sort="Serrano, Sergio V" uniqKey="Serrano S" first="Sergio V." last="Serrano">Sergio V. Serrano</name>
</noRegion>
</country>
<country name="Italie"><noRegion><name sortKey="Mansutti, Mauro" sort="Mansutti, Mauro" uniqKey="Mansutti M" first="Mauro" last="Mansutti">Mauro Mansutti</name>
</noRegion>
<name sortKey="Mariani, Paola" sort="Mariani, Paola" uniqKey="Mariani P" first="Paola" last="Mariani">Paola Mariani</name>
</country>
<country name="Australie"><noRegion><name sortKey="Chan, Arlene" sort="Chan, Arlene" uniqKey="Chan A" first="Arlene" last="Chan">Arlene Chan</name>
</noRegion>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Lipatov, Oleg" sort="Lipatov, Oleg" uniqKey="Lipatov O" first="Oleg" last="Lipatov">Oleg Lipatov</name>
</noRegion>
<name sortKey="Chan, Stephen" sort="Chan, Stephen" uniqKey="Chan S" first="Stephen" last="Chan">Stephen Chan</name>
<name sortKey="Wardley, Andrew" sort="Wardley, Andrew" uniqKey="Wardley A" first="Andrew" last="Wardley">Andrew Wardley</name>
</country>
<country name="Autriche"><noRegion><name sortKey="Greil, Richard" sort="Greil, Richard" uniqKey="Greil R" first="Richard" last="Greil">Richard Greil</name>
</noRegion>
</country>
<country name="Suisse"><noRegion><name sortKey="Moore, Nicola" sort="Moore, Nicola" uniqKey="Moore N" first="Nicola" last="Moore">Nicola Moore</name>
</noRegion>
<name sortKey="Pallaud, Celine" sort="Pallaud, Celine" uniqKey="Pallaud C" first="Celine" last="Pallaud">Celine Pallaud</name>
<name sortKey="Prot, Sylvie" sort="Prot, Sylvie" uniqKey="Prot S" first="Sylvie" last="Prot">Sylvie Prot</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005123 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005123 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:13-0188852
   |texte=   AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri